The estimated Net Worth of Herbert Virgin is at least $4.09 Million dollars as of 9 August 2022. Herbert Virgin owns over 78,093 units of Vir Biotechnology Inc stock worth over $2,044,875 and over the last 4 years he sold VIR stock worth over $73,215. In addition, he makes $1,968,860 as Executive Vice President of Research and Chief Scientific Officer at Vir Biotechnology Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Herbert Virgin VIR stock SEC Form 4 insiders trading
Herbert has made over 65 trades of the Vir Biotechnology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 78,093 units of VIR stock worth $189,766 on 9 August 2022.
The largest trade he's ever made was exercising 78,093 units of Vir Biotechnology Inc stock on 9 August 2022 worth over $189,766. On average, Herbert trades about 6,566 units every 12 days since 2020. As of 9 August 2022 he still owns at least 262,500 units of Vir Biotechnology Inc stock.
You can see the complete history of Herbert Virgin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Herbert Virgin biography
Dr. Herbert Virgin M.D., Ph.D. serves as Executive Vice President of Research and Chief Scientific Officer of the Company.D. serves as Executive Vice President of Research and Chief Scientific Officer of the Company. serves as Executive Vice President of Research and Chief Scientific Officer of the Company. He maintains an association with Washington University as a non-tenured faculty member. Earlier in his career, Dr. Virgin trained in internal medicine at Brigham and Women’s Hospital in Boston and in infectious diseases at Barnes Hospital in St. Louis. He is a member of the American Society for Clinical Investigation, the Association of American Physicians, the American Academy of Microbiology and the National Academy of Sciences. Dr. Virgin previous served on the Board of Reviewing Editors of Science, and is currently on the Editorial Boards of Cell and Cell Host and Microbe. Dr. Virgin received his A.B. in Biology, his M.D. and his Ph.D. in Immunology from Harvard University and Harvard Medical School.
What is the salary of Herbert Virgin?
As the Executive Vice President of Research and Chief Scientific Officer of Vir Biotechnology Inc, the total compensation of Herbert Virgin at Vir Biotechnology Inc is $1,968,860. There are 2 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.
How old is Herbert Virgin?
Herbert Virgin is 64, he's been the Executive Vice President of Research and Chief Scientific Officer of Vir Biotechnology Inc since 2018. There are 9 older and 14 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
What's Herbert Virgin's mailing address?
Herbert's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO, CA, 94158.
Insiders trading at Vir Biotechnology Inc
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I..., and Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
What does Vir Biotechnology Inc do?
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
What does Vir Biotechnology Inc's logo look like?
Complete history of Herbert Virgin stock trades at Vir Biotechnology Inc
Vir Biotechnology Inc executives and stock owners
Vir Biotechnology Inc executives and other stock owners filed with the SEC include:
-
George Scangos,
President, Chief Executive Officer, Director -
Howard Horn,
Chief Financial Officer, Secretary -
Herbert Virgin,
Executive Vice President of Research and Chief Scientific Officer -
Vicki Sato,
Independent Chairman of the Board -
Dr. Herbert W. Virgin IV, M.D., Ph.D.,
Exec. VP of Research & Chief Scientific Officer -
Dr. Herbert W. Virgin IV,
Exec. VP of Research & Chief Scientific Officer -
Dr. George A. Scangos Ph.D.,
Pres, CEO & Director -
Dr. Ann M. Hanly Ph.D.,
Exec. VP & Chief Technology Officer -
Phil Pang,
Chief Medical Officer -
Dr. George A. Scangos,
Pres, CEO & Director -
Dr. Phillip Pang M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Steven J. Rice,
Chief Admin. Officer -
Saira Ramasastry,
Independent Director -
Robert Perez,
Independent Director -
Phillip Sharp,
Independent Director -
Dr. Klaus Frueh,
Co-Founder & Scientific Advisor -
Robert More,
Independent Director -
Dipchand Nishar,
Independent Director -
Robert Nelsen,
Independent Director -
Elliott Sigal,
Independent Director -
Janet Napolitano,
Director -
Michael Kamarck,
Chief Technology Officer -
Jay Parrish,
Chief Business Officer -
Johanna Friedl-Naderer,
Exec. VP & COO -
Irene Pleasure J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Heather Rowe Armstrong,
VP of Investor Relations -
Dr. Aine M. Hanly Ph.D.,
Chief Technology Officer -
Dr. Louis J. Picker M.D.,
Co-Founder & Scientific Advisor -
Dr. Klaus Frueh Ph.D.,
Co-Founder & Scientific Advisor -
Dr. Neera Dahiya Ravindran M.D., MBA,
VP and Head of Investor Relations & Strategic Communications -
Dr. Louis J. Picker,
Co-Founder & Scientific Advisor -
Dr. Lawrence Corey,
Co-Founder & Scientific Advisor -
Permanent Fund Corp Alaska,
-
& Melinda Gates Foundation ...,
-
Johanna Friedl Naderer,
EVP & Chief Operating Officer -
Steven J. Rice,
Chief Administrative Officer -
Venture Partners Ix, Llcarc...,
-
Endurance (Cayman) Ltd Sb I...,
-
Dhabi Investment Authority ...,
-
Holdings (Private) Ltd Full...,
-
Program Ii (Co Invest Holdi...,
-
Mark Eisner,
EVP and Chief Medical Officer -
Klaus Frueh,
Director -
Venture Partners Ix, Llcarc...,
-
Kristina Burow,
Director -
Jeffrey S. Hatfield,
Director -
Norbert W Bischofberger,
Director -
Ramy Farid,
Director -
Sung Lee,
EVP & Chief Financial Officer -
Ann M. Hanly,
EVP & Chief Technology Officer -
Backer Marianne De,
Chief Executive Officer